|
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
High expression of PDE4D correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma.
|
31772658 |
2019 |
|
Brain Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders.
|
31013090 |
2019 |
|
Restrictive cardiomyopathy
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Epigenetic regulation of phosphodiesterase 4d in restrictive cardiomyopathy mice with cTnI mutations.
|
30900165 |
2019 |
|
CNS disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
These new data provide a rationale for exploring the therapeutic benefit of selective inhibitors of PDE1C, PDE4B and PDE4D in CNS disorders affecting cognition.
|
30800055 |
2019 |
|
Cognition Disorders
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Restoring PDE4D activity using an inhibitor rescues cognitive deficits in male mice but has no effect on female mice.
|
30732858 |
2019 |
|
Dermatitis, Atopic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we, for the first time, report statistically significant increases in expression of phosphodiesterase 4D (PDE4D) gene in peripheral blood mononuclear cells (PBMCs) and miR-203 in plasma from AD dogs compared to healthy controls.
|
31226136 |
2019 |
|
Eczema
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we, for the first time, report statistically significant increases in expression of phosphodiesterase 4D (PDE4D) gene in peripheral blood mononuclear cells (PBMCs) and miR-203 in plasma from AD dogs compared to healthy controls.
|
31226136 |
2019 |
|
Encephalomyelitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
3b (PDE4B IC<sub>50</sub> = 0.39 ± 0.13 μM with ∼27 and > 250 fold selectivity for PDE4B over PDE4D and C, respectively) showed effects in Zebrafish experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis when dosed at 3, 10 and 30 mg/kg intraperitoneally.
|
31035240 |
2019 |
|
Obsessive-Compulsive Disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The present study is the first to verify the associations of single nucleotide polymorphisms rs1838733 of the PDE4D gene with obsessive-compulsive disorder in a Chinese Han population.
|
31469783 |
2019 |
|
Psychotic Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Thus, rs165940 represents the most likely functional variant for major mental illness at the PDE4D locus in the Finnish population, increasing risk broadly to psychotic disorders.
|
31138891 |
2019 |
|
Thyroid Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
People with the TT allele in PDE4D (rs27178) should be made aware of an increased risk of subclinical thyroid disease.
|
30485936 |
2019 |
|
Depressive Symptoms
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
These studies demonstrated levels of serum androgens, C-reactive protein, and advanced glycation endproducts; thrombin generation; left ventricular mass; depressive symptoms; phosphodiesterase 4D single nucleotide polymorphisms; coagulation factor XII gene; peak thrombus generation; and lower cognitive functioning were independent risk factors for ischemic stroke in older adults.
|
31127075 |
2019 |
|
Secondary malignant neoplasm of liver
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High level of PDE4D was significantly associated with clinical stage (<i>P</i> = 0.004), T classification (<i>P</i> = 0.003), lymph node metastasis (<i>P</i> = 0.022) and liver metastasis (<i>P</i> = 0.038).
|
31772658 |
2019 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High level of PDE4D was significantly associated with clinical stage (<i>P</i> = 0.004), T classification (<i>P</i> = 0.003), lymph node metastasis (<i>P</i> = 0.022) and liver metastasis (<i>P</i> = 0.038).
|
31772658 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, the expression and significance of PDE4D in pancreatic ductal adenocarcinoma (PDAC) have not been elucidated.
|
31772658 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<b>Results</b>: We found that PDE4D was significantly up-regulated in PDAC tumor tissues compared to those paired adjacent noncancerous tissues at both protein and mRNA levels.
|
31772658 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Further analysis of clinical samples indicated that low PDE4D expression and high level of TPL2 phosphorylation were correlated to the development and poor prognosis in bladder cancer patients.
|
30482227 |
2018 |
|
Bladder Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Further analysis of clinical samples indicated that low PDE4D expression and high level of TPL2 phosphorylation were correlated to the development and poor prognosis in bladder cancer patients.
|
30482227 |
2018 |
|
Cachexia
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
These novel findings confirm a major role for PDE4B in skeletal muscle proteolysis in burn injury and suggest that an innovative therapy based on PDE4B-selective inhibitors could be developed to treat skeletal muscle cachexia in burn injury without the fear of causing emesis, which is associated with PDE4D inhibition.
|
29693432 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
It was hypothesized that HOXA11-AS may have a function in NSCLC by regulating the expression of miR-642b-3p and PDE4D, which laid the foundation for the further elucidation of the potential molecular mechanisms of NSCLC.
|
29616096 |
2018 |
|
Squamous cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The area under the curve of PDE4D was 0.905 [95% confidence interval (CI), 0.879-0.931] for patients with lung adenocarcinoma and 0.665 (95% CI, 0.606-0.725) for patients with squamous cell carcinoma.
|
29616096 |
2018 |
|
Cardiovascular Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
This study explored the associations between subjective sleepiness and single-nucleotide polymorphisms (SNPs) in candidate genes within oxidative stress, inflammatory, and neuronal pathways, which may contribute to sleepiness and downstream cardiovascular disease risk: Cytochrome B-245, Alpha Polypeptide (CYBA), Cytochrome B-245, Beta Polypeptide (CYBB), Neutrophil Cytosolic Factor (NCF2), Tumor Necrosis Factor-Alpha (TNFA), and Phosphodiesterase 4D (PDE4D).
|
29783161 |
2018 |
|
Malignant neoplasm of stomach
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic variants of rs2274223 in PLCE1 at 10q23.33 (per G allele: odds ratio (OR) = 1.26, 95% confidence interval (CI): 1.16-1.38, P = 6.51 × 10<sup>-8</sup>), rs10052657 in PDE4D at 5q11.2 (per C allele: OR = 1.12, 95% CI: 1.01-1.25, P = 3.28 × 10<sup>-2</sup>) and rs671 in ALDH2 at 12q24.12 (per A-allele: OR = 0.83, 95% CI: 0.75-0.91, P = 1.14 × 10<sup>-4</sup>) were significantly associated with GC risk.
|
30202044 |
2018 |
|
Osteochondrodysplasias
|
0.010 |
Biomarker
|
group |
BEFREE |
Our findings of PDE4D variants in two cases of acroscyphodysplasia support that PDE4D may be responsible for this severe skeletal dysplasia.
|
30006632 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
The area under the curve of PDE4D was 0.905 [95% confidence interval (CI), 0.879-0.931] for patients with lung adenocarcinoma and 0.665 (95% CI, 0.606-0.725) for patients with squamous cell carcinoma.
|
29616096 |
2018 |